CRP and head and neck cancer: Based on a stricter serum CRP level (3 mg/L) cutoff, the high-sensitivity mGPS (HS-mGPS) has been reported to be a better prognostic indicator than conventional mGPS for various malignancies (11–13), and this superiority was also indicated in a study on head and neck cancer (14).